Phase 2 trial results of lixisenatide published
The full results of the one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results, indicating that the treatment may slow the progression of motor symptoms. Researchers have reported that the...
Learn more
Biotech Inhibikase develops new drug for Parkinson’s
Researchers have published laboratory data demonstrating the neuroprotective effects of a new potential drug for Parkinson’s called IkT-148009.
Results of FAIRPARK-II deferiprone trial published
The results of the most recent study of deferiprone in people with Parkinson’s (the FAIRPARK-II study) have been published in the New England Journal of Medicine.
A sub-study of azathioprine in Parkinson’s
There is increasing evidence that inflammation and the immune system might have contributory roles in the development and progression of Parkinson’s.
Inhibikase makes a case for c-Abl
Research has suggested that in some cases of Parkinson’s a protein called c-Abl tyrosine kinase is abnormally over-active and this contributes to nerve cell inflammation and eventual cell death. The biotech company, Inhibikase, has been developing a drug which dampens down abnormal c-Abl protein.
Nicotinamide riboside for Parkinson’s: pilot results published
Researchers in Norway have published the promising results of a pilot clinical study of nicotinamide riboside for people with Parkinson’s.